Contineum Therapeutics, Inc. Class A Common Stock – NASDAQ:CTNM
Contineum Therapeutics, Inc. Class A Common Stock stock price today
$9.3
-5.1
-35.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Contineum Therapeutics, Inc. Class A Common Stock stock price monthly change
-30.67%
month
Contineum Therapeutics, Inc. Class A Common Stock stock price quarterly change
-30.67%
quarter
Contineum Therapeutics, Inc. Class A Common Stock key metrics
Market Cap | 347.22M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeContineum Therapeutics, Inc. Class A Common Stock stock price history
Contineum Therapeutics, Inc. Class A Common Stock stock forecast
Contineum Therapeutics, Inc. Class A Common Stock financial statements
Average Price Target
$32
Potential upside: 244.08%
Analysts Price target
Financials & Ratios estimates
| 2023 | 50M | 22.72M | 45.44% |
|---|
| 2024-05-16 | -0.46 | -3.55 |
|---|
| 2023 | 130386000 | 198.32M | 152.1% |
|---|
| 2022 | -20.12M | 22.29M | -1.23M |
|---|---|---|---|
| 2023 | 19.34M | -65.56M | 56.17M |
Contineum Therapeutics, Inc. Class A Common Stock alternative data
| Jun 2024 | 31 |
|---|---|
| Jul 2024 | 31 |
| Dec 2024 | 31 |
Contineum Therapeutics, Inc. Class A Common Stock other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 7200 |
-
What's the price of Contineum Therapeutics, Inc. Class A Common Stock stock today?
One share of Contineum Therapeutics, Inc. Class A Common Stock stock can currently be purchased for approximately $9.3.
-
When is Contineum Therapeutics, Inc. Class A Common Stock's next earnings date?
Unfortunately, Contineum Therapeutics, Inc. Class A Common Stock's (CTNM) next earnings date is currently unknown.
-
Does Contineum Therapeutics, Inc. Class A Common Stock pay dividends?
No, Contineum Therapeutics, Inc. Class A Common Stock does not pay dividends.
-
How much money does Contineum Therapeutics, Inc. Class A Common Stock make?
Contineum Therapeutics, Inc. Class A Common Stock has a market capitalization of 347.22M. Contineum Therapeutics, Inc. Class A Common Stock earned 22.72M US dollars in net income (profit) last year or -$3.55 on an earnings per share basis.
-
What is Contineum Therapeutics, Inc. Class A Common Stock's stock symbol?
Contineum Therapeutics, Inc. Class A Common Stock is traded on the NASDAQ under the ticker symbol "CTNM".
-
What is Contineum Therapeutics, Inc. Class A Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Contineum Therapeutics, Inc. Class A Common Stock?
Shares of Contineum Therapeutics, Inc. Class A Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Contineum Therapeutics, Inc. Class A Common Stock have?
As Dec 2024, Contineum Therapeutics, Inc. Class A Common Stock employs 31 workers.
-
What is Contineum Therapeutics, Inc. Class A Common Stock's official website?
The official website for Contineum Therapeutics, Inc. Class A Common Stock is contineum-tx.com.
-
Where are Contineum Therapeutics, Inc. Class A Common Stock's headquarters?
Contineum Therapeutics, Inc. Class A Common Stock is headquartered at 10578 Science Center Drive, San Diego, CA.
-
How can i contact Contineum Therapeutics, Inc. Class A Common Stock?
Contineum Therapeutics, Inc. Class A Common Stock's mailing address is 10578 Science Center Drive, San Diego, CA and company can be reached via phone at (858) 333-5280.
-
What is Contineum Therapeutics, Inc. Class A Common Stock stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Contineum Therapeutics, Inc. Class A Common Stock in the last 12 months, the avarage price target is $32. The average price target represents a 244.08% change from the last price of $9.3.
Contineum Therapeutics, Inc. Class A Common Stock company profile:
Contineum Therapeutics, Inc. Class A Common Stock
contineum-tx.comExchange:
NASDAQ
Full time employees:
31
Industry:
Biotechnology
Sector:
Healthcare
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
10578 Science Center Drive
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001855175
ISIN: US21217B1008
:
